Skip to main content
Figure 4 | Molecular Pain

Figure 4

From: Analgesia for neuropathic pain by dorsal root ganglion transplantation of genetically engineered mesenchymal stem cells: initial results

Figure 4

Analgesic effects from GDNF-secreting MSC engraftment. (A) In the absence of injury, transplantation of EGFP-MSCs did not change the frequency of hyperalgesia response upon fully noxious stimulation by Pin (top panel) or the threshold for withdrawal from mechanical stimulation with von Frey fibers (bottom panel). (B) In the setting of neuropathic pain from L5 SNL, animals transplanted with either type of cells (EGFP-MSCs or GDNF/EGFP-MSCs) at the time of nerve injury all developed mechanical hyperalgesia (Pin) and allodynia (von Frey) by 7 days later (left panels), which persisted for 21 days. However, those animals receiving GDNF/EGFP-MSCs showed a smaller reduction in withdrawal threshold, demonstrated by area under the curve (AUC) analysis comparing groups (right panel), *p < 0.05. (C) Immunoblots show detection of GDNF-2A (top panel) and EGFP (middle panel) derived from transplanted GDNF/EGFP-MSCs in DRGs (from 2 different animals) harvested 3 weeks after transplantation, while endogenous GDNF was not detected in control DRGs contralateral to the injury.

Back to article page

Molecular Pain

ISSN: 1744-8069

Contact us